These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 677435)

  • 1. Pharmacokinetics of pancuronium in patients with normal and impaired renal function.
    Buzello W; Agoston S
    Anaesthesist; 1978 Jun; 27(6):291-7. PubMed ID: 677435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative clinical pharmacokinetics of tubocurarine, gallamine, alcuronium and pancuronium.
    Buzello W; Agoston S
    Anaesthesist; 1978 Jul; 27(7):313-8. PubMed ID: 150804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of intercompartmental disposition and excretion of tubocurarine, gallamine, alcuronium and pancuronium in patients with normal and impaired renal function.
    Buzello W; Agoston S
    Anaesthesist; 1978 Jul; 27(7):319-21. PubMed ID: 150805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.
    Bencini AF; Scaf AH; Sohn YJ; Meistelman C; Lienhart A; Kersten UW; Schwarz S; Agoston S
    Anesth Analg; 1986 Mar; 65(3):245-51. PubMed ID: 2869722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum concentrations of pancuronium in anuric patients (author's transl)].
    Buzello W; Ruthven-Murray J
    Anaesthesist; 1976 Sep; 25(9):440-3. PubMed ID: 970599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat.
    Miller RD; Agoston S; van der Pol F; Booij LH; Crul JF; Ham J
    J Pharmacol Exp Ther; 1978 Nov; 207(2):532-8. PubMed ID: 712635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The metabolism of pancuronium in man].
    Buzello W
    Anaesthesist; 1975 Jan; 24(1):13-8. PubMed ID: 1130635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients.
    Sohn YJ; Bencini AF; Scaf AH; Kersten UW; Agoston S
    Anesth Analg; 1986 Mar; 65(3):233-9. PubMed ID: 2869721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man.
    Miller RD; Agoston S; Booij LH; Kersten UW; Crul JF; Ham J
    J Pharmacol Exp Ther; 1978 Nov; 207(2):539-43. PubMed ID: 712636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of pancuronium bromide.
    Somogyi AA; Shanks CA; Triggs EJ
    Eur J Clin Pharmacol; 1976 Sep; 10(5):367-72. PubMed ID: 789085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats.
    Upton RA; Nguyen TL; Miller RD; Castagnoli N
    Anesth Analg; 1982 Apr; 61(4):313-6. PubMed ID: 6121522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs.
    Booij LH; Vree TB; Hurkmans F; Reekers-Ketting JJ; Crul JF
    Anaesthesist; 1981 Jul; 30(7):329-33. PubMed ID: 6115592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic model for pancuronium.
    Hull CJ; Van Beem HB; McLeod K; Sibbald A; Watson MJ
    Br J Anaesth; 1978 Nov; 50(11):1113-23. PubMed ID: 718781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide.
    Somogyi AA; Shanks CA; Triggs EJ
    Eur J Clin Pharmacol; 1977 Aug; 12(1):23-9. PubMed ID: 332502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic modelling with pancuronium.
    Evans MA; Shanks CA; Brown KF; Triggs EJ
    Eur J Clin Pharmacol; 1984; 26(2):243-50. PubMed ID: 6723764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition decomposition analysis for pharmacodynamic modeling of the link compartment.
    Cheng H; Jusko WJ
    Biopharm Drug Dispos; 1996 Mar; 17(2):117-24. PubMed ID: 8907718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neuromuscular blocking action of vecuronium in normal patients and in patients with no renal function and interaction vecuronium-tobramycin in renal transplant patients.
    Vanacker BF; Van de Walle J
    Acta Anaesthesiol Belg; 1986; 37(2):95-9. PubMed ID: 2875595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.